Cohance Lifesciences to host investor meets in Mumbai, Hyderabad

0 min read | Published on 17 Sept 2026, 01:09 PM |Updated on 17 Sept 2026, 01:09 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Cohance Lifesciences hosts JP Morgan India Conference meet in Mumbai on September 22, 2026
Management to attend JP Morgan Roadshow in Hyderabad on September 24, 2026
Interactions include both group and one-on-one sessions with analysts
Schedule subject to change; no unpublished price-sensitive info to be shared

*this image is generated using AI for illustrative purposes only.

Cohance Lifesciences will host analysts and institutional investors in Mumbai and Hyderabad this month. The management team is scheduled for group and one-on-one sessions.

The company disclosed the schedule pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No unpublished price-sensitive information will be shared during these interactions.

Meeting Schedule

The management will attend the following conferences:

Date	Conference	Location	Format
September 22, 2026	JP Morgan India Conference	Mumbai	Group and One-on-One
September 24, 2026	JP Morgan Roadshow	Hyderabad	Group

The schedule remains subject to change due to exigencies involving the company, analysts, or institutional investors. Sisir K. Mishra, Company Secretary and Compliance Officer, signed the intimation.

Historical Stock Returns for Cohance Lifesciences

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.63%	-0.76%	-0.15%	+49.94%	-55.59%	-18.22%

How might the insights shared at the JP Morgan conferences influence institutional sentiment and short-term trading volume for Cohance Lifesciences?

What specific strategic updates or pipeline milestones is the management likely to highlight to attract long-term investor interest?

Could the focus on one-on-one sessions in Mumbai indicate a targeted effort to secure commitments from key domestic institutional players?

Cohance Lifesciences

View Company Insights

View All News

Cohance Lifesciences gets four USFDA Form 483 observations at plant

0 min read | Published on 05 Sept 2026, 09:45 AM |Updated on 07 Sept 2026, 05:49 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Cohance Lifesciences received four observations on FDA Form 483
Inspection was conducted at the company's formulation plant
USFDA issued the standard regulatory document post-inspection
Company plans to initiate corrective actions and respond timely
Observations do not constitute final regulatory action

*this image is generated using AI for illustrative purposes only.

Cohance Lifesciences received four observations on FDA Form 483 following a USFDA inspection at its formulation plant. The company plans to initiate corrective measures and respond promptly.

Inspection outcome and regulatory observations

The USFDA inspection concluded with the issuance of FDA Form 483, a standard regulatory document used by the US Food and Drug Administration to record inspectional observations noted by investigators. Cohance Lifesciences received four observations on the form following the inspection at its formulation plant.

Company's planned response

Cohance Lifesciences has indicated plans to begin corrective measures and respond to the observations promptly. FDA Form 483 observations do not constitute a final regulatory action; companies are typically given an opportunity to address the noted findings through a formal response.

Detail	Information
Regulatory body	USFDA
Document issued	FDA Form 483
Number of observations	4
Plant type	Formulation plant
Company's stated action	Initiate corrective measures and respond promptly

Historical Stock Returns for Cohance Lifesciences

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.63%	-0.76%	-0.15%	+49.94%	-55.59%	-18.22%

What specific nature do the four FDA observations hold, and how might they impact Cohance's current export approvals to the US market?

How long is the expected timeline for Cohance Lifesciences to submit its formal response, and what are the potential consequences if the FDA deems the corrective actions insufficient?

Could these observations lead to a Warning Letter or Import Alert in the near future, potentially disrupting supply chains for key US clients?

Cohance Lifesciences

View Company Insights

View All News